A clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly schizophrenia and other neuropsychiatric conditions. Its lead asset, KarXT, targets muscarinic receptors and has drawn investor attention as a potential new mechanism for tr...
1 member of Congress has disclosed 1 trade in Karuna Therapeutics, Inc. (KRTX), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-04-10 | Daniel Goldman | sell | $1K – $15K |